Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2006) 11 P477

ECE2006 Poster Presentations Endocrine tumours and neoplasia (116 abstracts)

Insulin-like growth factor-i signalling in tamoxifen sensitive and tamoxifen resistant breast cancer cells

CJ McVittie 1 , S Khalaf 2 , W Ogunkolade 2 , R Carpenter 1 , SA Bustin 3 & PJ Jenkins 2


1Department of Breast Surgery, Barts Hospital, London, United Kingdom; 2Department of Endocrinology, Barts and the London, London, United Kingdom; 3Department of Academic Surgery, Barts and the London, London, United Kingdom.


Background: Due to its cross-talk with estrogen receptor (ER) signalling, increased IGF-I signalling through the IGF-I receptor (IGF-IR) has been postulated as an important factor in the development of tamoxifen resistance in breast cancer.

Aims: To investigate the importance of IGF-I signalling in tamoxifen resistant (TR) and wild-type (WT) MCF-7 breast cancer cells by (i) assessing cell proliferation in response to IGF-I and tamoxifen and (ii) using small interfering RNA (siRNA) to silence IGF-IR expression.

Methods: We have previously established a TR cell line from a parent MCF-7 cell line. (i) WT & TR cells were cultured in media ±50 ng/ml IGF-I ±10−7 M 4-OH tamoxifen. Cell proliferation was assessed every 24 hours using the MTS assay. (ii) WT & TR cells were transfected with 200 nM IGF-IR-specific siRNA for 15 days. Cell proliferation was assessed every 3 days. Previous optimisation has verified >90% reduction in IGF-IR levels in siRNA transfected cells.

Results: (i) WT cell proliferation showed a significant increase when cultured with IGF-I and decrease when cultured with tamoxifen. In contrast TR cells showed no significant response to IGF-I or tamoxifen (mean cell number ± S.D. expressed as % of media only).

Table 1
WT + IGF-IWT + TamTR + IGF-ITR + Tam
24 hrs146.3±16*65.3± 6*97.5±1389.9±7
48 hrs206.9±11*61.1± 3*110.2±8100.1±3
72 hrs259.3±28*56.7± 3*103.7±8100.4±9

(ii) Silencing of the IGF-IR caused a rapid decline in WT cell number but significantly less effect was seen in the TR cells (47.2±10% vs. 93.4±7% at day 3**, 23.8±8% vs. 59.6±9% at day 9** and 14.0±5% vs. 49.2±7% at day 15**). (*P<0.0001; **P<0.0001).

Conclusions: In contrast to expectation, development of tamoxifen resistance appears to also involve resistance to the effects of IGF-I and IGF-IR signalling. This may reflect the close interaction between the ER and IGF-IR signalling pathways.

Volume 11

8th European Congress of Endocrinology incorporating the British Endocrine Societies

European Society of Endocrinology 
British Endocrine Societies 

Browse other volumes

Article tools

My recent searches

No recent searches.